- Home
- DSL vs VRDN Comparison
DSL vs VRDN Comparison
Compare DSL & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSL
- VRDN
- Stock Information
- Founded
- DSL 2013
- VRDN 2006
- Country
- DSL United States
- VRDN United States
- Employees
- DSL N/A
- VRDN N/A
- Industry
- DSL Trusts Except Educational Religious and Charitable
- VRDN Medical Specialities
- Sector
- DSL Finance
- VRDN Health Care
- Exchange
- DSL Nasdaq
- VRDN Nasdaq
- Market Cap
- DSL 1.4B
- VRDN 1.3B
- IPO Year
- DSL N/A
- VRDN N/A
- Fundamental
- Price
- DSL $12.31
- VRDN $16.41
- Analyst Decision
- DSL
- VRDN Strong Buy
- Analyst Count
- DSL 0
- VRDN 11
- Target Price
- DSL N/A
- VRDN $38.80
- AVG Volume (30 Days)
- DSL 434.7K
- VRDN 722.5K
- Earning Date
- DSL 01-01-0001
- VRDN 08-06-2025
- Dividend Yield
- DSL 10.83%
- VRDN N/A
- EPS Growth
- DSL N/A
- VRDN N/A
- EPS
- DSL N/A
- VRDN N/A
- Revenue
- DSL N/A
- VRDN $305,000.00
- Revenue This Year
- DSL N/A
- VRDN N/A
- Revenue Next Year
- DSL N/A
- VRDN $17,102.33
- P/E Ratio
- DSL N/A
- VRDN N/A
- Revenue Growth
- DSL N/A
- VRDN 5.90
- 52 Week Low
- DSL $10.58
- VRDN $9.90
- 52 Week High
- DSL $13.24
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- DSL 64.85
- VRDN 47.57
- Support Level
- DSL $12.00
- VRDN $15.70
- Resistance Level
- DSL $12.16
- VRDN $17.79
- Average True Range (ATR)
- DSL 0.07
- VRDN 0.96
- MACD
- DSL 0.03
- VRDN -0.18
- Stochastic Oscillator
- DSL 98.48
- VRDN 23.40
About DSL DoubleLine Income Solutions Fund of Beneficial Interests
DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).